Mark Versavel
Arlington, Massachusetts
Overview
Clinical pharma consultant as President of vZenium LLC. Currently appointed as Fractional CMO at Consano Bio, Senior Vice President at Axonis Therapeutics, acting CMO at Afasci, and clinical consultant at Alzheon, and Bial. Former CMO and Senior VP at Eliem Therapeutics, and Scientific Advisory Board member at Confo. Providing clinical development support to biotech and pharmaceutical companies, building on >30 years experience in clinical development and medical affairs in multiple CNS indications including stroke, neuropathic pain, multiple sclerosis, Parkinson's, restless legs, Huntington'
About
Clinical pharma consultant as President of vZenium LLC. Currently appointed as Fractional CMO at Consano Bio, Senior Vice President at Axonis Therapeutics, acting CMO at Afasci, and clinical consultant at Alzheon, and Bial. Former CMO and Senior VP at Eliem Therapeutics, and Scientific Advisory Board member at Confo. Providing clinical development support to biotech and pharmaceutical companies, building on >30 years experience in clinical development and medical affairs in multiple CNS indications including stroke, neuropathic pain, multiple sclerosis, Parkinson's, restless legs, Huntington's, Alzheimer's, epilepsy, autism, schizophrenia, bipolar disorder and depression. Track record of achievements through multi-disciplinary team-leadership with a cooperative leadership style, motivating teams to top performance and persisting though difficult periods, always looking for solutions and creative ways to move the project forward. Strong analytical and judgment skills and capability to make decisions in the face of uncertainty. Flexibility and capacity to learn and succeed in new situations and cultures, with extensive international experience (Belgium, Netherlands, Germany, France, USA). •Bringing Alzheon's drug ALZ-801 to Phase 2-3 in Alzheimer's Disease. •Completed 2 Phase 2 trials with Z160 in neuropathic pain at Zalicus, and demonstrated efficacy of Z944 in laser evoked pain model. •Created pharmaco-EEG and neuropsychological test unit, performed validation studies that led to PhD thesis on the use of psychometric tests in healthy volunteers. •Clinical pharmacology lead for nimodipine (Nimotop), ipsapirone CR, BAYx 3702, metrifonate •Clinical development for ziprasidone (Geodon) in schizophrenia and bipolar disorder, pregabalin (Lyrica) in epilepsy and neuropathic pain, sumanirole in Parkinson’s disease and Restless Legs Syndrome, AMPA antagonist in stroke •Medical Affairs and Phase IV experience with eslicarbazepine acetate (Aptiom) in epilepsy, eszopiclone (Lunesta) in insomnia, Lyrica and gabapentin (Neurontin) in neuropathic pain and epilepsy, Rebif and Betaferon / Betaseron in MS,